ProPhase Labs, Inc. Debt Securities, Available-for-sale, Gain (Loss)
ProPhase Labs, Inc. (PRPH) reported Debt Securities, Available-for-sale, Gain (Loss) of $3.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2023-11-13
- ProPhase Labs, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2023-09-30 was $111.00K.
- ProPhase Labs, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2023-06-30 was -$1.00K.
- ProPhase Labs, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2023-03-31 was -$107.00K.
- ProPhase Labs, Inc. debt securities, available-for-sale, gain (loss) for the quarter ending 2022-09-30 was -$6.00K.
| Period end | Debt Securities, Available-for-sale, Gain (Loss) 3 month | Debt Securities, Available-for-sale, Gain (Loss) 6 month | Debt Securities, Available-for-sale, Gain (Loss) 9 month |
|---|---|---|---|
| 2023-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $110.00K derived: sum of 2 quarters · filed 2023-11-13 | $3.00K 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$108.00K 10-Q · filed 2023-08-11 | |
| 2023-03-31 | -$107.00K 10-Q · filed 2023-05-12 | ||
| 2022-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$13.00K derived: sum of 2 quarters · filed 2023-11-13 | -$192.00K 10-Q · filed 2023-11-13 |
| 2022-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$186.00K 10-Q · filed 2023-08-11 | |
| 2022-03-31 | -$179.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |